Monday, March 16, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Amazon consolidates healthcare groups under veteran exec, shakes up pharmacy leadership

Amazon senior executive Neil Lindsay, a key figure in the growth of the company’s Kindle and Prime businesses, has been tapped to lead the company’s newly combined healthcare organization, Amazon confirmed.

“This new consolidated healthcare structure brings together the Amazon Pharmacy, Care, and Diagnostics businesses to advance higher quality of care, and to develop more customer-centric ways for patients to get the healthcare services, products, and medications they need,” an Amazon spokesperson said in a statement.

John Love, currently vice president of Alexa Shopping, will become vice president of Amazon Pharmacy in January. Amazon Pharmacy reportedly hasn’t yet lived up to external expectations since it was launched a year ago.

TJ Parker and Elliot Cohen, founders of Pillpack, led Amazon’s pharmacy business since its acquisition of the prescription-by-mail company in 2018.

Source: Geek Wire

https://www.geekwire.com/2021/amazon-consolidates-healthcare-groups-under-veteran-exec-shakes-up-pharmacy-leadership/

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

GLP-1 Drugs Have Moved Past Weight Loss. Medicine Has Not Fully Caught Up.

Glucagon-Like Peptide–Based Therapies and Longevity: Clinical Implications from Emerging Evidence

Glucagon-like peptide–based therapies are increasingly used for weight management and glycemic control, but their potential impact on long-term survival remains uncertain. The clinical question addressed in this report is whether treatment with glucagon-like peptide receptor agonists is associated with reductions in all-cause mortality and age-related morbidity beyond their established metabolic effects. This question matters because these agents are now prescribed across broad patient populations, including individuals without diabetes, and long-term exposure may influence cardiovascular, oncologic, and neurodegenerative outcomes. Understanding whether...

Read more

Join Our Newsletter!